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Serological screening approaches have allowed for the identiﬁca-
tion of a large number of potentially relevant tumor antigens in
cancer patients. Within this group, cancer testis antigens repre-
sent promising targets for cancer immunotherapy, since they are
widely expressed in a variety of human cancer entities. In pancre-
atic cancer, however, there are only few data available about the
expression pattern and serological response to cancer testis anti-
gens and other serological-deﬁned tumor antigens. Therefore, we
investigated the IgG antibody response against 11 cancer testis
antigens (SCP-1, GAGE, LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-
5) recombinantly expressed on yeast surface (RAYS) in patients
with pancreatic cancer (n 5 96), chronic pancreatitis (n 5 18) and
healthy donors (n 5 48). We found in 14% of all patients antibody
responses to SCP-1, but not to other cancer testis antigens (GAGE,
LAGE-1a,-1b, CT-7, NY-ESO-1, SSX-1-5). Antibody response cor-
related with the expression of SCP-1 in the primary tumor of the
respective patient as shown by RT-PCR, immunohistochemistry
and Western blot. In contrast, no serological response to cancer
testis antigens was observed in healthy donors. The humoral
immune response against SCP-1 was associated with the size of tu-
mor, but not with other clinico-pathological parameters such as
histology, stage, presence of lymph node metastases, grading, age,
gender or gemcitabine treatment. In conclusion, antibody re-
sponse to cancer testis antigen SCP-1 is found in a proportion of
pancreatic carcinoma patients. These results indicate that identiﬁ-
cation of additional tumor antigens by serological screening of tu-
mor cDNA expression libraries by RAYS is a promising goal in
pancreatic cancer.
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The recent progress in surgery,1 radiotherapy2 and chemother-
apy3 of pancreatic cancer has not changed the 5-year survival rate
of this tumor entity, which remains 3–5% for all stages.4 There-
fore, efforts to ﬁnd therapeutic alternatives for pancreatic cancer
patients have to be enforced. Immunotherapy has the potential to
provide anti-tumor activity that can be integrated into conven-
tional surgical, radio- and chemotherapeutic treatment without
signiﬁcantly adding to therapy-associated toxicity.
A prerequisite for the development of tumor-speciﬁc immuno-
therapeutic strategies is the existence of tumor antigens, i.e., genes
that are either exclusively or preferentially expressed in malignant
tissues, compared with normal tissues. According to their expres-
sion pattern and the speciﬁcity of the immune responses they
evoke, antigens expressed by human neoplasms can be classiﬁed
into different groups.5 These include the cancer testis antigens
(CTA), also called cancer germline antigens (e.g. the MAGE fam-
ily), the differentiation antigens (e.g. tyrosinase), the products of
viral genes (e.g. HPV-16), mutated genes (e.g. mutated p53), dif-
ferentially spliced genes (e.g. LDH C6), overexpressed genes or
ampliﬁed genes (e.g. eIF-4g 7) as well as common autoantigens
that are expressed by the malignant cells of a tumor (e.g. U1
snRNP).5 In pancreatic cancer, only few tumor antigens are known
and most of them are overexpressed in tumor cells, but will also
be found at a certain level in normal human cells (e.g. CEA, Her-
2/neu, MUC-1, CA19-9, CA 242, 17-1A and mesothelin).8,9 The
expression of these genes in normal tissue limits their use as tar-
gets for speciﬁc immunotherapy. Therefore, the identiﬁcation of
more, especially more speciﬁc, tumor antigens is warranted.
In recent years, a powerful serological technique using high-
titred immunoglobulin G antibodies obtained from the sera of can-
cer patients has been developed for the identiﬁcation of tumor
antigens. By means of SEREX, the serological identiﬁcation of
antigens by recombinant expression cloning, it was possible to
identify a multitude of new cancer antigens in different tumor enti-
ties, which are documented in the international SEREX database
(www2.licr.org/Cancer ImmunomeDB/).10 For example, several
new cancer testis antigens were deﬁned by this approach (i.e.,
NY-ESO-1, SSX-1-5, SCP-1 and CT-7).11 Cancer testis antigens
are characterized by their expression in a variety of malignant
tumors but not in normal tissue, with the exception of testis. They
were identiﬁed by the screening of recombinant expression of tu-
mor tissue from non-pancreatic origin (i.e. melanoma, esophagus
carcinoma),12 but were found to be present in pancreatic carci-
noma samples.13 For some of these antigens, it has been demon-
strated that they do not only elicit a humoral B-cell response but
also a cellular CD81/CD41 T cell response.14 This means that
SEREX-deﬁned tumor antigens might be appropriate target anti-
gens for either antibody- or vaccine-based approaches.
However, there is growing evidence that the antigen repertoire
detectable by the conventional SEREX approach is limited.5 This
might be attributed in part to the fact that potential antigens that
are subject to posttranslational modiﬁcations remain undetected
in bacterial expression systems, which generally are not capable of
post-translationally modifying recombinantly expressed proteins.
As a consequence, we recently established a eukaryotic cDNA ex-
pression system in yeast (RAYS) to overcome this SEREX-inherent
problem.15,16 Yeast has the advantage that recombinant proteins can
be expressed on the cell surface as part of the cell wall in a more
naturally folded and partially glycosylated manner.16–18 The ability
of the yeast display system to detect potentially relevant tumor anti-
gens not recognized by conventional SEREX demonstrates the
power of this new tool.15
Considering these facts, it seems to be promising to use SEREX
and/or RAYS in combination with a cDNA expression library of
pancreatic adenocarcinoma tissue to identify novel pancreas carci-
noma-associated antigens. The prerequisite for such an approach
would be a sufﬁciently strong humoral immune response against
pancreatic carcinoma antigens. However, at the present time there
are only few data available about the extent of antibody responses
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against tumor antigens in pancreatic cancer,19 and it cannot be
excluded that humoral immune response is suppressed by pan-
creatic carcinoma-related factors.20 Against this background, the
objectives of this study were (a) to examine systemically the hu-
moral immune response to cancer testis antigens as representative
tumor antigens in pancreatic cancer and (b) to test the applicability
of RAYS for the screening of antibody responses in this tumor
entity.
Material and methods
Tissues and cell lines
This study was approved by the local ethical review board
(‘‘Ethikkommission der €Arztekammer des Saarlandes’’) and per-
formed according to the Declaration of Helsinki. After informed
consent, serum samples were collected from 100 patients with
inoperable or operable adenocarcinoma of the pancreas. In a pro-
portion of patients (76%), tumor samples were obtained from pan-
creaticoduodenectomy (Whipple operation) or pancreatectomy at
the Saarland University Medical School (Homburg, Germany), at
the Rostock University Medical School (Germany), at the Univer-
sity of Heidelberg Medical School (Mannheim, Germany) and at
the University of Hamburg Medical School (Germany) between
January 1997 and November 2000. Tumor stage and grading were
determined according to the UICC (Union International contre
Cancer).21
Reverse transcriptase-PCR for the detection and ampliﬁcation
of cancer testis antigens in tumor samples
cDNA was obtained from different tissues and RT-PCR was
performed as previously described using primer pairs given in
Table I.13 cDNA plasmids coding for the SSX and GAGE family
members were kindly supplied by Dr. Y. Chen/Dr. A. Gure (Weill
Medical College of Cornell University, New York) and by Dr. B.
van den Eynde (Ludwig Institute for Cancer Research, Brussels,
Belgium), respectively.
Immunohistochemistry
Immunohistochemical staining of SCP-1 protein was done in
parafﬁn-embedded sections with mouse monoclonal anti-SCP-1-
antibody (SC554, IgG1), as described earlier.
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Expression of cancer testis antigens on yeast surface (RAYS)
The ampliﬁed codogen regions of the CT-antigens GAGE-2,
NY-ESO-1, SSX-1, SSX-2, SSX-3, SSX-4, SSX-5, SCP-1.1, SCP-
1.2, SCP-1.3, SCP-1.1-2, SCP-1.2-3, SCP-1.2-4, LAGE-1a,
LAGE-1b and CT-7 were cloned into the multiple cloning site
of the pYD1 plasmid (Invitrogen, Leiden, The Netherlands;
Table I).15 Plasmids were introduced into Saccharomyces cerevi-
siae EBY100, using a commercially available transformation kit
(EasyComp, Invitrogen, The Netherlands), according to the manu-
facturer’s recommendations. Thereafter, yeast were spread on
MD-Leu plates (0.67% yeast nitrogen base, 2% dextrose, 0.01%
leucine, 1.5% agar) for the selection of transformed clones. Colo-
nies were picked and cultured [in YPD/CAA-Glu: 1% yeast
extract, 2% polypeptone and 2% dextrose or in YNB/CAA-Glu:
2% dextrose, 0.67% yeast nitrogen base and 0.5% Casamino acids
(Difco, Livonia, Minnesota, USA)] with constant agitation to an
approximate OD (600 nm) of 4 (30C, 4 h). To induce surface pro-
tein expression, yeast were pelleted by centrifugation, resuspended
to an OD (600 nm) of 0.6 in YNB/CAA-Gal and grown with agita-
tion for additional 48 h (20C).
Immunoﬂuorescence staining for ﬂow cytometry
Recombinant antigen expression on yeast surface (RAYS) was
used for serological analysis as described (Fig. 1).16 In brief, 104–
105 transformed and induced yeast cells containing tumor cDNA
fragment—pYD1 plasmids—were collected by centrifugation (2000 g,
5 min), washed with PBS and incubated with 100 ll of pre-
absorbed serum (1:100 dilution, RT, 30 min) with occasional agi-
tation. Parental control yeast transformed with empty pYD1 vector
(Ctrl pYD1) served for human sera preabsorption (Fig. 3b). Then,
cells were washed, secondary biotinylated anti-human-IgG Fcg
speciﬁc serum (Dianova, Hamburg, Germany) was added and the
mixture incubated was with occasional agitation (dilution 1:200,
RT, 30 min). Finally, R-Phycoerythrin-conjugated Streptavidin
(Dianova, Hamburg, Germany) was added (dilution of 1:200, RT,
15 min) and washed twice with PBS (0.1% Tween) before analyz-
ing the sera reactivity by ﬂow cytometry (FACScan; Becton Dick-
inson, Heidelberg, Germany). Expression control for the cloned
antigens was performed by the detection of expressed His-tag or
X-press-tag, using the speciﬁc biotinylated anti-penta-His anti-
body (1:500, Qiagen, Hilden, Hamburg) or the anti-X-Press anti-
body (1:500, Invitrogen, Leiden, The Netherlands), respectively
TABLE I – PRIMER PAIRS USED FOR AMPLIFICATION OF CDNA FRAGMENTS
50 GAGE-2 GAATTCATGAGTTGGCGAGGAAGATCG
30 GAGE-2 CTCGAGACACTGTGCTTGCTTTTGACCACC
50 NY-ESO-1 GAATTCCAGGCCGAAGGCCGGGGGCAC
30 NY-ESO-1 CTCGAGTTAGCGCCTCTGCCCTGAGGG
50 LAGE-1a GAATTCCAGGCCGAAGGCCAGGGCACAGG
30 LAGE-1a CTCGAGTTAGCGCCTCTGCCCTGAG
50 LAGE-1b GAATTCCAGGCCGAAGGCCAGGGCACAGG
30 LAGE-1b CTCGAGCTAAATGTGAGGGGCAGAGAACATCAC
50 SSX-1 GAATTCAACGGAGACGACACCTTTGCAAAG
30 SSX-1 CTCGAGCTCGTCATCTTCCTCAGGGTCAC
50 SSX-2,4 GAATTCAACGGAGACGACGCCTTTG
30 SSX-2,4 CTCGAGCTCGTCATCTTCCTCAGGGTC
50 SSX-3 GAATTCAACGGAGATGACACCTTTGCAAGG
30 SSX-3 CTCGAGCTCATCATCTTCCTCAGGATCGCTG
50 SSX-5 GAATTCAACGGAGACGATGCCTTTGTACGG
30 SSX-5 CTCGAGCTCGTCATCTTCCTGAGGGTCG
50 SCP-1.1 GGATCCAGTGTGGTGATGGAAAAGCAAAAGCCCTTTGC
30 SCP-1.1 ATACCTGCTTTTCCTTGTCATTTATTTCC
50 SCP-1.2 GGATCCAGTGTGGTGGTGCAAGCTGAGAATTCCAGACTGG
30 SCP-1.2 AGTGTGAAGTTAATTCAGTATTCTTAAGC
50 SCP-1.3 GGATCCAGTGTGGTGAGTGAACAGTATTATTCAAAAGAG
30 SCP-1.3 ATTCTTTTGCCTCTCTTTTGAGTTTTTCC
50 SCP-1.4 AGAGCATCTTTGGAGATTGAACTATCC
30 SCP-1.4 AACAAATAACTTTTCAGCTTCTTTTAG
50 CT-7 CCAAAGAATTCGGCACAATTGCCTCAGGGG
30 CT-7 CTCGAGTCACTCAGAAGAGAAGCTGGGGGA
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(Figs. 3a and 3b). Thirty thousand cells were counted and the ratio
between the intensity of the signal measured on antigen expressing
and non-expressing (Ctrl-pYD1) yeast was calculated for each
individual sample.
Western blot analysis
Serum antibody responses against endogenous SCP-1 protein
were tested by standard Western blot analysis.15,22 Brieﬂy, 1.5,
0.5 and 0.15 mg of testis and 2 mg of the pancreatic tissues (pan-
creatic carcinoma, chronic pancreatitis and normal pancreas) were
diluted in SDS-loading buffer and electrophoresed on a 8% SDS
polyacrylamide gel. Then, separated proteins were blotted with a
semi-dry blotter (Bio-Rad, Munich, Germany) on a PVDF-mem-
brane (Bio-Rad), and SCP-1 protein was recognized by a previ-
ously determined optimal dilution of mouse monoclonal anti-SCP-
1-antibody 554 (6 lg/ml). Anti-mouse conjugated peroxidase
antibody (1:3,000, Bio-Rad) and enhanced chemoluminescence
kit (Amersham Pharmacia, Freiburg, Germany) were used for
detection (Fig. 6b and 6c).
Statistical analysis
Crosstables were tested by v2- or Fisher exact test where appro-
priate. To interpret the signiﬁcance of differences observed, p val-
ues <0.05 were considered as signiﬁcant.
Results
Study population
In total, we investigated the humoral immune response against
11 cancer testis antigens in 96 sera of patients with pancreatic
carcinoma (SCP-1, GAGE2, LAGE-1a, LAGE-1b, SSX-1-5, NY-
ESO-1, CT-7). In a certain number of cases (n 5 24), tumor tissue
of the primary tumor was available for investigation of protein
and mRNA expression by immunohistochemistry and RT-PCR.
The average age of the involved patients was 62 years and the
women to men ratio were 1:1.2. Half of the patients (47%) had
metastatic disease, and the other half (53%) was submitted to
diagnostic or therapeutic laparotomy. Inoperable pancreatic carci-
noma was detected in 13% of the patients and 40% had been
treated by pancreaticoduodenectomy (Whipple operation) or pan-
createctomy. The majority of operable patients (72%) suffered
from locally advanced pancreatic cancer, i.e., UICC tumor stages
II (pT3N0M0) or III (pT1-3N1M0).21 The complete clinico-patho-
logical characteristics of the patients, including grading, were
available for 63 cases (65%, Table II).
Expression of cancer testis antigens on yeast surface
The concept for the expression of cDNA fragments on the yeast
surface and the serological detection by human immunoglobulin
has been described before15,16 and is illustrated in Figure 1. In
summary, the expression of cancer-speciﬁc antigens is induced on
the surface of S. cerevisiae as fusion proteins to Aga2p, which are
his-tagged at the carboxy terminus. Correct expression of the re-
spective antigen is demonstrated by ﬂow-cytometric detection of
FIGURE 1 – Schematic diagram of surface expression of CT anti-
gens on yeast cell wall. The vector pYD1 with inducible promoter was
used for high yield expression of CT antigens on the surface of S. cer-
evisiae as a tightly regulated fusion protein to Aga2p. Antigens
expressed in this way can be utilized for detection of reactive IgG
serum antibodies derived from cancer patients and healthy donors.
Correct expression was conﬁrmed by staining of the C-terminal penta-
his epitope.
FIGURE 2 – Recombinant antigen expression of the SCP-1 protein fragments 1, 2, 3, 1-2, 2-3 and 2-4 on yeast surface. (a) Schematic diagram
of the SCP-1 fragments cloned into pYD1 expression plasmid (bp, base pair). (b) Correct protein induction and cell surface expression was ana-
lyzed for SCP-1 protein fragments 1, 2, 3, 1-2, 2-3 and 2-4, as described. Antigen expression on induced (closed curve) and noninduced (open
curve) yeast was detected using an anti-Histidin antibody.
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the His-tag by an anti-His-antibody (Figs. 2b and 3a, closed
curve). If no human cDNA fragment is inserted in the pYD1 vec-
tor (control pYD1 yeast), Aga2p is expressed on the yeast surface
and can be detected by the anti-His-antibody (Fig. 3b, closed
curve). Non-induced yeast cells do not express the carboxy-termi-
nal His-tag (Figs. 2b, 3a and 3b, open curve). In this way, strong
antigen expression on the yeast surface was observed for the tu-
mor antigens GAGE-2, LAGE-1a, LAGE-1b, CT-7, NY-ESO-1
and SSX-1 up to SSX-5. However, we failed to express the full
length protein of SCP-1 on yeast surface. To include SCP-1 in the
analysis, the protein was divided into different fragments (SCP-1
fragment 1, 1-2, 2, 2-3, 3, 2-4) (Fig. 2a), which revealed satisfac-
tory expression levels of SCP-1 fragments 1, 2, 3, 1-2 and 2-3 on
yeast surface (Fig. 2b), whereas the expression of SCP-1 fragment
2-4 was low (Fig. 2b). An explanation for the insufﬁcient expres-
sion of the C-terminal SCP-1 fragment 2-4 on yeast surface could
be the basic character of this protein domain, which may inﬂuence
transport or ﬁxation to the cell wall.
Serological analysis of 11 cancer testis antigens with
pancreatic cancer sera
Importantly, correctly expressed cancer speciﬁc antigens can be
detected by IgG antibodies present in the sera of cancer patients.
As an example, the reactivity of such a serum with the cancer tes-
tis antigen SCP-1 (fragment 2-3) is demonstrated in Figure 3c
TABLE II – PATIENTS CHARACTERISTICS AND SERUM REACTIVITY
AGAINST SCP-1
Characteristic
Number of patients
per group
Number of patients
with seroreactivity
against SCP-1
Age
>60 years 43 8 (19)
60 years 20 3 (15)
Gender
Male 32 7 (22)
Female 31 4 (13)
pT status
pT1-2 15 0 (0)
1
pT3-4 48 11 (23)
pN status
pN0 25
2 32 (12)
pN1 25
2 52 (20)
Stage
I/II 23 3 (13)
III/IV 40 8 (20)
Grading
Well/moderately
differentiated
35 6 (17)
Poor 28 5 (18)
Total 63 11 (17)
Values in parentheses are in percentages.
1p5 0.041, T1-2 versus T3-4 by v
2-test.–2n5 50 for pN.
FIGURE 3 – Quality control of antigen-expression on yeast cell wall exemplary for the cancer-testis-antigen SCP-1 (fragment 2-3). (a) Correct
expression of antigen is demonstrated by ﬂow-cytometric detection with anti-Histidine antibody on induced yeast (closed curve) containing the
SCP-1-pYD1 vector. Non-induced yeast serves as negative control (open curve). (b) Correct expression of Aga2p on induced parenteral yeast
transformed with empty pYD1 vector (Ctrl pYD1) detected by anti-Histidin antibody (closed curve). This yeast served as negative control in
comparison to SCP-1-pYD1 vector containing yeast to exclude cross reactions of sera against yeast or vector epitopes [(c), open curve]. Non-
induced yeast serves as negative control (open curve). (c) Reactivity of pancreatic cancer serum diluted 1:100 with SCP-1-pYD1 (closed curve).
Ctrl pYD1 serves as negative control (open curve). (d) Strength of the humoral immune response against SCP-1-pYD1 examined by serum dilu-
tion. Positive reaction can be observed up to a dilution of 1:5000 in highly reactive sera (upper line) and up to a dilution of 1:1000 in moderately
reactive sera (middle line), whereas negative sera did not show signiﬁcant dilution effects (lower line).
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(closed curve). As negative control, serum was incubated with
yeast containing empty pYD1 vector (control pYD1 yeast 5 ctrl
pYD1) and did not demonstrate a positive reaction (Fig. 3c, open
curve). In this way, we analyzed the humoral immune response
against 11 different cancer testis antigens in 96 sera from pancre-
atic adenocarinoma patients. For this purpose, a ﬁnal panel of 16
yeast clones expressing cancer testis antigens (SSX-1-5, LAGE-
1a, LAGE-1b, NY-ESO-1, CT-7, GAGE-2, SCP-1 fragment 1, 1-
2, 2, 2-3, 3, 2-4) was produced. In order to evaluate the speciﬁcity
of the antibody responses for cancer patients, tumor sera were
compared to 46 sera from healthy donors and 18 sera from patients
with acute or chronic pancreatitis. As described earlier, all sera
were diluted 1:100 and were tested in parallel on induced yeast
expressing the Aga2 fusion protein alone (control pYD1 yeast) or
fused to the respective cancer testis antigen (test yeast, p.e. SCP-
1-pYD1) (Fig. 3c). The ratio between sera reactivity on test yeast
and control pYD1 yeast was calculated. Values above 2 were con-
sidered as positive signals. Humoral immune response against
cancer testis antigen SCP-1 was found in 14 out of 96 pancreatic
cancer patients (14.6%, Fig. 4). For SSX-1, one positive antibody
response was detected in the total of 96 cases. A positive serum
response against other cancer testis antigens was not observed
(Fig. 4). A detailed analysis of the serum response against differ-
ent SCP-1 fragments demonstrated that most of the reactive sera
are directed against fragments 2, 3 and 2-3, which represent the
central part of the SCP-1 protein, including amino acids 781-2443
(Fig. 5). However, it is important to note that analysis of serum
reactivity against the C-terminal region of SCP-1 was limited by
the low expression of fragment 2-4 on yeast surface (Fig. 2b),
which may lead to false negative results. Sera from normal donors
(n 5 48) and from patients with acute (n 5 3) or chronic pancrea-
titis (n 5 15) did not react with any SCP-1 protein fragments
expressed on the yeast surface (Fig. 5). To analyze the strength of
the immune response against SCP-1, reactive sera were diluted
in different concentrations (1:50, 1:100, 1:200,1:500, 1:1,000,
1:5,000, 1:104, 1:105, 1:106). Reactivity in lower dilutions corre-
lated with high values concerning the ratio between sera reactivity
on test yeast and control pYD1 yeast. For example, a positive
reaction can be observed up to a dilution of 1:5,000 in highly reac-
tive sera (Fig. 3d, upper line) and up to a dilution of 1:1,000 in
moderately reactive sera (Fig. 3d, middle line), whereas negative
sera did not show signiﬁcant dilution effects (Fig. 3d lower line).
Serum response and mRNA expression of cancer testis antigens
The analysis of tissue samples of pancreatic adenocarcinoma
revealed SCP-1 mRNA expression in 62.5% (15/24) cases (se-
lected samples in Fig. 6c). In 9 out of these 15 cases (60%) a hu-
moral immune response was detected by RAYS, whereas no se-
rum reactivity was found for RT-PCR negative cases (p 5 0.05 by
Fisher exact test). Cancer testis antigens GAGE-2 and SSX-4 were
found to be expressed in 16% (4/24) and 5% (1/24) of the cases,
respectively, but no humoral immune response was observed. Nei-
ther serum reactivity nor mRNA expression was shown for CT7
(0/24), SSX-1, SSX-2, SSX-3 (0/24), NY-ESO-1 (0/24) and CT-7
(0/24). The mRNA-expression of LAGE-1a, -1b and SSX-5 was
not investigated. Cancer testis antigen mRNA expression was not
found in normal pancreas (n 5 4, Fig. 6c). Despite the detection
of SCP-1 mRNA in 2 out of 8 and GAGE mRNA in 1 out of 9
patients with chronic pancreatitis, we did not observe any humoral
immune response against SCP-1 or GAGE in 15 sera derived from
patients with chronic pancreatitis.
Serum response and protein expression of SCP-1
In a limited number of pancreatic carcinoma patients who were
mRNA- and seropositive for SCP-1 (n 5 4, Fig. 6c), tumor tissue
samples were available as parafﬁn-embedded sections and were
investigated for the expression of SCP-1 by immunohistochem-
istry, using a monoclonal anti-SCP-1-antibody. SCP-1 positive tu-
mor cells were demonstrated in 2 of 4 patients with seroreactivity
against SCP-1, whereas we could not detect SCP-1 protein expres-
sion by immunohistochemistry in 4 samples from SCP-1 seroneg-
ative patients. As demonstrated previously,13 SCP-1 positive
tumor cells showed a ﬁne granular cytoplasmatic or a spotted
nuclear staining. A typical example is shown in Figure 6a. SCP-1
FIGURE 4 – Serological response
against CT antigens in pancreatic
carcinoma. Dot plot diagram of
96 pancreatic cancer sera incubated
with yeast expressing CT antigens
as listed in the X axis. Patients sera
were diluted 1:100 and analyzed by
ﬂow cytometry for binding as
described. The ratio between the in-
tensity of staining of test yeast and
control pYD1 yeast was calculated.
Values above 2 were considered as
positive signals (line).
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expression in pancreatic carcinoma samples derived from patients
with SCP-1 seroreactivity was conﬁrmed by Western blot analysis
after the correct staining procedure had been established on testis
tissue (Fig. 6b). Detection of a protein with molecular weight of
114 kDa was found in protein extracts of SCP-1-RT-PCR-positive
tumor probes, but not in SCP-1-RT-PCR-negative probes or
extracts obtained from chronic pancreatitis or normal pancreas
(Fig. 6c).
Serum response to SCP-1 and correlation with
clinicopathological parameters
Pancreatic carcinoma patients with pT status 3 or 4 demon-
strated seroreactivity against SCP-1 in 23% of the cases, whereas
none of the patients with pT status 1 or 2 had a humoral immune
response against SCP-1 (p 5 0.041 by v2-test, not signiﬁcant if a
signiﬁcance level adjusted to multiple testing is used). This indi-
cates that patients with larger tumor and antigen masses tend to
develop more frequently a serological response against SCP-1
than patients with smaller tumors. Seroreactivity against SCP-1
did not correlate with age, gender, pN-status, stage or grading
(Table II). In addition, seroreactivity was found in almost the same
portion of patients not treated or treated with gemcitabine [(18%
(7/40) versus 17% (4/23), respectively)]. This means that seroreac-
tivity was not affected by the treatment of patients with gemcita-
bine, which was reported to compromise humoral immune re-
sponses.23
Discussion
Despite some evidence for a tumor-speciﬁc immune response
in patients with pancreatic cancer, its extent and prognostic impor-
tance is still a matter of debate. In this study, we investigated the
serological response to different cancer testis antigens by means
of a novel system for recombinant expression of tumor antigens in
eukaryotic yeast (RAYS). In a proportion of patients, we noticed
an antibody response to the cancer testis antigen SCP-1, whereas
no seroreactivity was found against this antigen in patients with
acute or chronic pancreatitis or in healthy donors. This demon-
strates that a strong tumor-speciﬁc humoral immune response to a
SEREX-deﬁned tumor antigen is present in patients with pancre-
atic carcinoma. Moreover, it might be an indication that other so
far unknown tumor antigens may be identiﬁed by techniques based
on the screening of sera obtained from patients with pancreatic
carcinoma.
SCP-1 is the most frequently found antigen in pancreatic carci-
noma (60%), regarding the mRNA expression.13 The observed hu-
moral immune response to this cancer testis antigen also suggests
a relevant protein expression of SCP-1 in pancreatic carcinoma.
This is additionally supported by the simultaneous detection of
SCP-1 mRNA (by RT-PCR) and SCP-1 protein (by Western Blot
and immunohistochemistry) in tumor samples of SCP-1-seroposi-
tive cases. Moreover, we could recently demonstrate a HLA-class
I24 and HLA-class-II-restricted25 T cell response against SCP-1,
indicating an integrated immune response involving T and B cells
speciﬁc for this antigen in cancer patients. With the restriction that
data are only available at the level of mRNA expression, the sec-
ond most frequently expressed cancer testis antigen is GAGE
(16%). Nevertheless, we could not detect antibody responses
against this antigen, a ﬁnding which is, to our knowledge, in
agreement with the published literature. GAGE was originally
deﬁned by reverse immunology using a GAGE-speciﬁc T cell
clone,26 which could indicate that GAGE elicits a cellular but pos-
sibly not a humoral immune response.27 Another rather methodi-
cal reason might be that RAYS is not sensitive enough to detect
anti-GAGE antibodies, although its sensitivity for other CT anti-
gens is at least equivalent to Western blotting or ELISA.16 Other
cancer testis antigens are very rarely (SSX-4, 2%) or not at all
(SSX-1, SSX-2, NY-ESO-1 and CT-7) found to be expressed in
pancreatic adenocarcinoma, as shown in this present and a more
FIGURE 5 – Serological response
against different SCP-1 protein
fragments in 96 patients with pan-
creatic carcinoma (PC), 18 patients
with chronic pancreatitis (PD) and
46 healthy individuals (N). Dot
plot diagram of sera incubated
with yeast expressing SCP-1 frag-
ments 1, 1-2, 2, 2-3, 3 and 2-4.
Patients sera were diluted 1:100
and analyzed by ﬂow cytometry as
described.
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extensive prior investigation.13 In line with these expression data,
we could not discover a serological immune response against
these antigens.
The humoral immunogenicity of SCP-1 had originally been
demonstrated in a patient with renal carcinoma.28 SCP-1 (or
SYCP-1/HOM-TES-14) is involved in meiotic chromosome pair-
ing29 and is frequently found in other neoplasms (between 30 and
50%), including breast carcinomas30 and gastrointestinal can-
cers.11,31,32 In breast carcinoma, we found a similar frequency of
patients with serum reactivity against SCP-1 (12%) as in pancre-
atic carcinoma. In pancreatic cancer, serological responses against
other tumor antigens like MUC-1 or mutated p53 are reported to
be present in a similar range, i.e. 7–22% of patients.33–36 Notably,
responses against both MUC-1 and p53 were found in healthy
donors and inﬂammatory processes like chronic pancreatitis.35,36
In contrast, we did not observe any humoral immune response to
SCP-1 in healthy donors and patients with acute or chronic pan-
creatitis. This observation may be related to the fact that MUC-1
and p53 are present in many or even all normal tissues. SCP-1
expression, in contrast, is almost exclusively restricted to cancer
cells and germline cells, which usually are not accessible to the
immune system. Surprisingly, SCP-1 expression was demon-
strated in rare cases of chronic pancreatitis.13 This is in line with
previous reports of similarities in gene expression shared by ade-
nocarcinoma of the pancreas and chronic pancreatitis, i.e. Ki-ras,
and supports the concept that alterations such as K-ras mutation or
CT antigen expression might transform into overt adenocarcinoma
if additional genetic changes occur.37 The lack of antibody re-
sponse as to this disease in our study may be due to the limited
number of samples tested.
FIGURE 6 – Detection of SCP-1 at mRNA and protein level in pancreatic cancer of seropositive patients. (a) Immunohistochemical detection
of SCP-1 by monoclonal antibody SC554 in the primary tumor of a patient with pancreatic adenocarcinoma. Staining was performed as
described in Material and Methods. Picture was taken with a ﬁnal magniﬁcation of 3800. (b) Detection of SCP-1 protein in testis by Westen
Blot. Descending amounts of protein extract (lane 1, 1.5 mg; lane 2, 0.5 mg; lane 3, 0.15 mg) separated in SDS gel electrophoresis were analyzed
for the presence of SCP-1 protein by SC554 monoclonal antibody (upper picture). Coomassie staining indicates different amounts of loaded tis-
sue sample (lower picture). A protein with the molecular weight of ~114 kDa was demonstrated and the strength of bands decreased in accord-
ance to the amount of protein. Theoretic MW of pSCP1:114 kDa. (c) Detection of SCP-1 protein in pancreatic tissue by Western Blot. Samples
of pancreatic cancer (n 5 3), chronic pancreatitis and normal pancreas were analyzed for the expression of SCP-1 protein by SC554 antibody.
SCP-1 was found in SCP-1-RT-PCR-positive tumor samples, but not in SCP-1-RT-PCR-negative samples or extracts obtained from chronic pan-
creatitis or normal pancreas (lower picture). All SCP-1-RT-PCR tumor samples were obtained from patients with seroreactivity against SCP-1
(upper picture).
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It is unclear why a humoral immune response against a particu-
lar antigen can be found only in a subset of patients with pancre-
atic carcinoma or other cancers. Immunogenicity may depend on
the level of expression, posttranslational modiﬁcation or other
types of protein processing, the extent of which may be varying
among tumors even of the same origin.38 Other factors that may
inﬂuence the immune response include the variability of tumors
and individuals as to MHC molecules and antigen presentation.39
This study demonstrates that recombinant antigen expression on
yeast surface is valuable for the detection of humoral immune
responses in pancreatic cancer. Therefore, this technique can also
be used to identify novel tumor antigens so far not detectable by
conventional SEREX analysis, which was previously performed
for pancreatic cancer by Nakatsura et al.40,41 We have recently
shown that in contrast to RAYS, recombinant bacterial protein
expression as performed by conventional SEREX approaches does
not display the entire spectrum of epitopes recognized by serologi-
cal immune responses against tumor antigens.15 Therefore, the use
of a eukaryotic expression system widens the potential spectrum
of antigens detected by the humoral immune system. This opens
the perspective that RAYS will enable the identiﬁcation of a new
quality of tumor antigens in pancreatic carcinoma, antigens that
have escaped detection to date because they elicit immune re-
sponses against posttranslationally modiﬁed or conformational
epitopes. With respect to therapeutic vaccine- or antibody-based
approaches, there is growing evidence that it is important to have
more than just one or two target antigens available. This is under-
lined by the heterogeneous expression of cancer testis and other
antigens in pancreatic cancer.13 Therefore, the next step will be a
systematic screening for new target antigens by means of the
RAYS technology. Hopefully, this will lead to the discovery of a
more extended list of appropriate targets to broaden our antigen
repertoire for the treatment of pancreatic cancer, because multiepi-
tope immunotherapeutic approaches targeting two or more tumor
antigens may represent the most promising strategy for the suc-
cessful treatment of cancer.
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